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Background: Subjects with Down syndrome (DS) have an increased susceptibility to infections and autoimmune
disorders. ATP, adenosine, and acetylcholine contribute to the immune response regulation, and NTPDase, aden-
osine deaminase (ADA) and acetylcholinesterase (AChE) are important enzymes in the control of the extracellu-
lar levels of these molecules. We evaluated the activities of these enzymes and the cytokine levels in samples of
DS individuals.
Methods: The population consisted of 23 subjectswith DS and 23healthy subjects. Twelvemilliliters of bloodwas
obtained from each subject and used for lymphocyte and serum preparation. Lymphocytes were separated on
Ficoll density gradients. After isolation, NTPDase and AChE activities were determined.
Results: The NTPDase activity using ADP as substrate was increased in lymphocytes of DS patients compared to
control (P b 0.05); however, no alterations were observed in the ATP hydrolysis. An increase was observed in
the AChE activity in lymphocytes and in ADA activity in serumof DS patients when compared to healthy subjects
(P b 0.05). In DS subjects, an increase in the levels of IL-1β, IL-6, TNF-α and IFN-γ and a decrease in the IL-10
levels were also observed (P b 0.05).
Conclusions: Alterations in the NTPDase, ADA and AChE activities as well changes in the cytokine levels may con-
tribute to immunological alterations observed in DS.© 2014 Elsevier B.V. All rights reserved.1. Introduction
Down syndrome (DS), also known as trisomy of 21, is a chromosom-
al alteration characterized by the presence of an extra copy of the chro-
mosome 21 [1,2]. It is the most common genetic disorder affecting 1 in
700 newborns [3]. Data from literature have shown that subjects with
DShave an increased susceptibility to infections and autoimmunedisor-
ders, which are the main causes of mortality and morbidity observed in
this genetic alteration [4].
The immune system dysfunction in DS has been associated to B lym-
phocyte decreased number, T-cell subset modiﬁcations as well as anti
and pro-inﬂammatory cytokine level alterations [5–8]. However, theem Bioquímica e Bioprospecção,
ntos, Universidade Federal de
Pelotas, RS, Brazil. Tel.: +55 53
).molecular mechanisms leading to immune defects and the contribution
of these alterations to the increased risk of infections have not been fully
elucidated.
Extracellular adenine nucleotides and nucleosides such as ATP and
adenosine have been recognized as key components of immune and in-
ﬂammatory processes [9]. ATP, acting through speciﬁc cell surface
purinergic receptors, is involved in pro-inﬂammatory actions such as
lymphocyte stimulation and proliferation as well as cytokine release, in-
cluding IL-2, IFN-γ, IL-1β and TNF-α [9,10]. In opposite, adenosine, a
product of ATP hydrolysis, exhibits potent anti-inﬂammatory and immu-
nosuppressive actions by inhibiting both proliferation of T cells and se-
cretion of pro-inﬂammatory cytokines, such as TNF-α and IFN-γ [11,12].
Extracellular ATP and adenosine levels are regulated by cell surface
ectoenzymes, such as ectonucleoside triphosphate diphosphohydrolase
(NTPDase) and adenosine deaminase (ADA). NTPDase1 (CD39) is in-
volved in the breakdown of ATP and ADP to AMP which is hydrolyzed
by ecto-5′-nucleotidase to adenosine [13,14]. ADA is considered a key
enzyme in purine metabolism, catalyzing the irreversible deamination
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ability [15]. Since NTPDase1 and ADA activities potentiallymodulate ex-
tracellular levels of pro-inﬂammatory ATP and anti-inﬂammatory
adenosine, the role of these enzymes has been evaluated in the patho-
genesis of immune and inﬂammatory diseases [16,17]. Indeed, the ac-
tivities of these enzymes have been altered in such conditions,
indicating the crucial role of NTPDase and ADA in the regulation of im-
munologic responses.
Acetylcholinesterase (AChE) is another enzyme involved in immune
functions. This enzyme is expressed in both T and B lymphocytes and
promotes the hydrolysis of the acetylcholine (ACh) to choline and ace-
tate [18]. ACh is known to promote anti-inﬂammatory actions by sup-
pressing the production of pro-inﬂammatory cytokines [19,20]. In this
line, AChE emerges as a potential contributor in the pathways control-
ling inﬂammatory and immune responses mediated by muscarinic
and nicotinic receptors [21]. Because of its key physiological role,
AChE activity has been studied in different pathological and experimen-
tal conditions [22].
Despite the importance of NTPDase1, AChE and ADA in modulating
inﬂammatory and immune responses, to the best of our knowledge,
there are few reports evaluating the activity of these enzymes in lym-
phocytes from DS subjects. Considering the alterations in lymphocyte
functions observed in DS, the aim of this studywas to evaluate NTPDase,
AChE and ADA activities in lymphocytes as well as the serum cytokine
levels of DS subjects.
2. Material and methods
2.1. Chemicals
Nucleotides, Trizma base, acetylthiocholine iodide (ASCh), 5,5′-dithio-
bis-2-nitrobenzoic acid (DTNB), Ficoll-Histopaque (LymphoprepTM) and
Malachite Green Carbinol Base were purchased from Sigma Chem. Co.
All other reagents used in the experiments were of analytical grade and
the highest purity.
2.2. Study population
The sample consisted of 23 DS and 23 healthy individuals (control
group). All the subjects included in this study were residents of the Pe-
lotas City, located in the south region of the state of the Rio Grande do
Sul (Brazil). The general characteristics of the individuals are shown in
Table 1. All subjects gave written informed consent to participate in
this study. Written informed consents were obtained from parents/
guardians of DS subjects. The Human Ethics Committee of the Health
Science Center from Universidade Federal de Pelotas approved the
study protocol. Twelve milliliters of blood was obtained from each sub-
ject by venous puncture and used for lymphocyte preparation and other
biochemical determinations described as follows.
2.3. Hematological determination
A complete hemogramwas performed in the blood samples collect-
ed in tubes containing 7.2 mg dipotassium EDTA as anticoagulant. The
hematological parameterswere carried outwith the aid of the automat-
ic counter Horiba ABX Pentra C+60 (Horiba ® ABX), which is anTable 1
Characteristics of Down syndrome (DS) and control individuals applied in this study.
Control DS
Number 23 23
Women 14 12
Men 9 11
Age of women 29.66 ± 9.91 29.33 ± 9.78
Age of men 26.15 ± 7.36 26.00 ± 7.1association of the principles of electrical impedance, ﬂow cytometry
and spectrophotometry for blood analysis. Hematological parameters
of the DS group and control are shown in Table 2. All the individuals
showed a hemogram compatible with their age and gender in accor-
dance with reference values.
2.4. Isolation of lymphocytes from human blood
Lymphocytes were isolated from human blood collected with EDTA
and separated on Ficoll-Histopaque density gradients as described by
[23]. Protein was measured by the Coomassie blue method according
to [24] using serum albumin as standard.
2.5. NTPDase enzyme assays in lymphocytes
After lymphocyte isolation, the NTPDase activity was determined as
described by [16] in a reaction medium containing 0.5 mM CaCl2, 120
mM NaCl, 5 mM KCl, 6 mM glucose and 50 mM Tris–HCl buffer
(pH 8.0), at a ﬁnal volume of 200 μl. Twentymicroliters of intactmono-
nuclear cells suspended in saline solutionwas added to a reactionmedi-
um (2–4 μg of protein) and pre-incubated for 10 min at 37 °C. The
enzyme reaction was initiated by the addition of substrate (ATP or
ADP) at a ﬁnal concentration of 2 mmol/l and it was stopped following
70 min of incubation by adding 200 μl of 10% trichloroacetic acid (TCA).
The released inorganic phosphate (Pi) was assayed by the method of
[11] usingMalachite Green as colorimetric reagent and KH2PO4 as stan-
dard. Controls were carried out by adding the enzyme preparation after
TCA addition to correct for non-enzymatic nucleotide hydrolysis. All
samples were run in triplicate and the speciﬁc activity is reported as
nmol Pi released/min/mg of protein.
2.6. AChE enzyme assays in lymphocytes
After lymphocyte isolation, the AChE activity was determined by
colorimetric assay [25] modiﬁed [26]. The reaction mixture was com-
posed of 1 mmol/l acetylthiocholine, 0.1 mmol/l 5,5′-dithio-bis-2-
nitrobenzoic acid (DTNB), and 0.1 mol/l phosphate buffer (pH 8.0)
and 100 μl of the intact mononuclear cells suspended in saline solution
was added to the reaction. The proteins of all samples were adjusted to
0.1–0.2 mg/ml. The absorbance was read on a spectrophotometer at
412 nm before and after incubation for 30 min at 27 °C. All samples
were run in triplicate and the speciﬁc activity of lymphocyte AChE
was calculated from the quotient between lymphocyte AChE activity
and protein content, and results are expressed as μmol of AcSch/h/mg
of protein.
2.7. ADA enzyme assay in blood serum
ADA activity in serumwas determined according to previous studies
[27]. Brieﬂy, 50 μl of serum reacted with 21 nmol/l of adenosine
(pH 6.5) and the incubation was carried out at 37 °C for 60 min. This
method is based on the direct production of ammonia when ADA acts
in excess of adenosine. Results were expressed in units per liter (U/l).
One unit (1 U) of ADA is deﬁned as the amount of enzyme required to
release 1 mmol of ammonia from adenosine per minute at standard
assay conditions.
2.8. Quantiﬁcation of cytokines
Cytokine quantiﬁcationwas assessed by ELISA using commercial kits
for human IFN-γ, TNF-α, IL-1β, IL-6 and IL-10 (eBio-Science), according
to the manufacturer's instructions. The cytokine presence and concen-
trationwere determined by the intensity of the colormeasured by spec-
trometry in a micro ELISA reader. Standard curves for the cytokines
ranged from 1 to 50 pg/ml for IL-1β, 2 to 200 pg/ml for IL-6, 4 to
Table 2
General characteristics of hematological parameters in Down syndrome subjects and control group.
Item DS (Men) DS (Women) Control (Men) Control (Women)
WBC (×103/mm3) 7.01 ± 2.04 5.54 ± 1.66 7.11 ± 1.36 7.76 ± 2.13
Neutrophils (×103/mm3) 3.66 ± 1.38 2.81 ± 1.39 3.77 ± 0.96 4.46 ± 1.53
Lymphocytes (×103/mm3) 2.39 ± 0.76 1.98 ± 0.61 2.35 ± 0.96 2.37 ± 0.76
Monocytes (×103/mm3) 0.58 ± 0.17 0.51 ± 0.25 0.59 ± 0.22 0.57 ± 0.15
Eosinophils (×103/mm3) 0.14 ± 0.11 0.11 ± 0.08 0.24 ± 0.14 0.22 ± 0.13
Basophils (×103/mm3) 0.04 ± 0.02 0.02 ± 0.01 0.03 ± 0.02 0.03 ± 0.02
Platelets (×103/mm3) 238.58 ± 58.41 236.33 ± 54.80 212.66 ± 37.09 247.66 ± 39.81
RBC (×106/mm3) 4.74 ± 0.43 4.22 ± 0.30 5.05 ± 0.38 4.43 ± 0.38
Hemoglobin (g/dl) 15.06 ± 1.40 13.57 ± 0.56 15.11 ± 1.0 13.26 ± 0.93
HCT (%) 45.35 ± 4.82 40.92 ± 2.53 44.4 ± 2.87 39.24 ± 3.07
MCV (fL) 95.5 ± 5.21 97.17 ± 6.76 88.06 ± 3.28 88.56 ± 3.79
MCHC (g/dl) 33.27 ± 0.71 33.23 ± 1.31 34.08 ± 2.86 33.83 ± 0.41
Variables are presented as means ± SEM. RBC (red blood cells), HCT (hematocrit), MCV (mean corpuscular volume), CHCM (mean corpuscular hemoglobin concentration), and WBC
(white blood cells).
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Fig. 1.NTPDase activity using ATP and ADP as substrates in lymphocytes fromDS and con-
trol subjects. Bars represent means ± SD. *Represents statistical difference control group
(Student's t test, P b 0.05, n = 23). NTPDase activity is expressed in nmol of Pi/min/mg
of protein.
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10.
2.9. Statistical analysis
Data were analyzed statistically by the Student's t-test for indepen-
dent samples. P b 0.05 was taken to indicate statistical signiﬁcance. All
data were expressed as mean ± SD.
3. Results
Table 1 presents general characteristics of the patients. The sample
consisted of 23 adult individuals with DS (12 female, mean age 29.33
± 9.78 and 11 male mean age 26.00 ± 7.1) and 23 healthy adult sub-
jects (14 female mean age 29.66 ± 9.91 and 9 male mean age 26.15
± 7.36) as a control group. The patients evaluated were not making
use of any therapy. Subjects were not affected by diabetes, myeloprolif-
erative disorders, or any type of dementia. They were not treated with
drugs that could affect the results of this study.
In the present study, a set of biomarkers of hematological changes
was analyzed in samples of adults with DS, which comprises: number
of cells (neutrophils, lymphocytes, monocytes, eosinophils and plate-
lets), WBC (white blood cells), RBC (red blood cells), HCT (hematocrit),
MCV (mean corpuscular volume), CHCM(mean corpuscular hemoglobin
concentration), and hemoglobin. No signiﬁcant differences were found
in any parameter between DS individuals and control group (Table 2).
Results obtained in the present study showed that both NTPDase
and AChE activities were altered in lymphocytes from DS individuals.
As can be observed in Fig. 1, NTPDase activity using ADP as substrate
was signiﬁcantly increased in lymphocytes from DS individuals when
compared to the control group (P b 0.05). However, no alteration was
observed in ATP hydrolysis (Fig. 1). In addition, a statistically signiﬁcant
increase was also observed in AChE activity from lymphocytes of DS
when compared to the control group (Fig. 2). Alterations in ADA activity
were also observed. Fig. 3 shows a signiﬁcant increase in serumADA ac-
tivity in DS subjects when compared to controls (P b 0.0001).
Fig. 4 exhibits the results obtained for cytokine levels in serum from
controls andDS subjects. As can be observed, IL-1β, IL-6, TNF-α and IFN-
γ levels were signiﬁcantly increased in serum from DS subjects when
compared to the control group (P b 0.003). In opposite, the IL-10 levels
decreased in adult DS subjects when compared to controls (P b 0.0001).
4. Discussion
Alterations in the number and function of lymphocyte subsets have
been correlated with the incidence of infections and autoimmune dis-
eases inDS [7,28]. In thepresent studywe evaluated the role of NTPDase
and AChE enzymes in lymphocytes of DS adult subjects in order to con-
tribute to the understanding of the impaired immunity observed in thisgenetic disorder. In addition, we also related these ﬁndings with hema-
tological and inﬂammatory parameters.
Attenuation of anti-inﬂammatory and increase of pro-inﬂammatory
mediators were shown in serum from DS individuals [8]. In the present
study DS individuals exhibited an increase in pro-inﬂammatory cytokine
levels such as IFN-γ, TNF-α, IL-1β and IL-6, while the anti-inﬂammatory
cytokine IL-10 was decreased. In agreement with our results, data from
literature have also demonstrated an increase of IFN-γ, TNF-α and IL-6
levels in adults [29,30] and adolescentswith DS [31]. Interestingly, Trotta
et al. [32] showed thatmononuclear cells fromperipheral blood of adults
with DS in culture released higher levels of IFN-γ and TNF-αwhen com-
pared to controls. In opposite to our results, Guazzarotti et al. (2009) and
Trotta et al. (2011) found increased values for IL-10.
The cytokines IL-1β and IL-6 are considered key orchestrators of im-
mune and inﬂammatory responses [33]. IL-1β stimulates B cell prolifer-
ation and maturation and induces immunoglobulin production, while
IL-6 secreted by T cells and macrophages stimulates the immune re-
sponse, which ultimately leads to inﬂammation [34]. In addition, IFN-
γ is considered a pro-inﬂammatory cytokine because it augments
control
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Fig. 2. AChE activity in lymphocytes from DS and control subjects. Bars represent means ±
SD. *Represents statistical difference from control group (Student's t test, P b 0.05, n = 23).
AChE activity is expressed in μmol of AcSch/h/mg of protein.
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kine of immune system by inhibiting the release of Th1 pro-
inﬂammatory cytokines, such as IL-2 and IFN-γ [35]. In this context,
the alterations in the levels of pro- and anti-inﬂammatory cytokines ob-
tained in our study reinforce the idea that alterations of cytokine release
may contribute to the disruption of an adaptative immune response de-
velopment [32].
It has been established that purinergic signaling contributes to the
regulation of inﬂammatory and immune responses [17,36]. Previous
studies have demonstrated that the activities of a number of purineme-
tabolizing enzymes are altered in lymphocytes and erythrocytes from
DS subjects suggesting that purinergic signaling is altered in this genetic
condition [37].
Extracellular ATP is involved in the pro-inﬂammatory function as a
stimulation and proliferation of lymphocyte [38]. In addition, ATP in-
duces secretion of cytokines like IL-2, IFN-γ, IL-1β, and TNF-α from acti-
vated lymphocytes and macrophages [9,10]. Hydrolysis of ATP by
NTPDase1 seems to play a crucial role in immune suppression as it
removes pro-inﬂammatory ATP and generates immunosuppressive
adenosine [39]. Surprisingly, our results show that only ADP hydrolysis
was increased in lymphocytes fromDS individuals, while the ATP hydro-
lysis was unchanged. The differential ATP and ADP hydrolysis pattern
fromDS lymphocytesmay result from the contribution of other enzymes
able tometabolize ATP. In addition, it is well known that DS is associated
to increased platelet aggregation, which can be an additional source of
extracellular ADP [13]. Thus, the increase in the ADP hydrolysis observed
in lymphocytes from DS subjects may contribute to adenosine produc-
tion. These alterationsmay represent an important compensatorymech-
anism to decrease inﬂammation and immune response in DS.
On the other hand we demonstrated an increase of ADA activity in
serum of DS subjects. Corroborating with our results, other studies
have also shown that ADA activity is increased in lymphocytes and
erythrocytes from DS subjects [37]. ADA is known to be divided in two
isoenzymes ADA1 and ADA2, which have different molecular weights0
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Fig. 3.Adenosine deaminase activity in serum fromDSand control subjects. Bars represent
means ± SD. *Represents statistical difference from control group (Student's t test,
P b 0.0001, n = 23). ADA activity is expressed in U/l.and kinetic properties. Interestingly, monocytes/macrophages and
serum contain ADA2with a low substrate afﬁnity [13]. SerumADA is in-
creased in various diseases; however, the origin of ADA in serum and
the mechanism by which serum ADA activity is increased have not
been fully elucidated yet [40].
Adenosine plays a crucial role in the regulation of inﬂammatory and
immune responses by inhibiting lymphocyte activation and decreasing
both Th1 and Th2 cytokine secretions through A2A receptor activation
[41]. In linewith this, it is important to note that in serumof DS subjects
the up-regulation of ADA activity may degrade adenosine, a molecule
with immunosuppressive and anti-inﬂammatory actions and thus con-
tribute to the high level of pro-inﬂammatory cytokines observed in this
study. Taken together, considering that NTPDase and ADA are involved
in the cell mediated immunity, this study suggests that activities of this
enzymes could be important biomarkers to determine the severity of in-
ﬂammatory and immune responses in DS.
It has also been demonstrated that AChE is expressed in both T and B
lymphocytes and has an important role in immune responses by rapidly
hydrolyzing ACh [42] which is known to have anti-inﬂammatory actions
and suppress the production of pro-inﬂammatory cytokines [18]. Studies
have demonstrated that the activation of the nicotinic receptors in
macrophages reduces signiﬁcantly the liberation of pro-inﬂammatory
cytokines such as TNF-α, IL-1β and IL-6, whereas the production of
anti-inﬂammatory cytokines, such as IL-10, is not affected [43,44]. The
inhibition of AChE activity was able to reduce the levels of TNF-α and
IL-1β in lymphocyte culture [21,22]. In this way, inhibitors of AChE re-
duce lymphocyte proliferation and the secretion of pro-inﬂammatory cy-
tokines and may attenuate inﬂammation by increasing the ACh
concentration in the extracellular space [21]. Here, we observed an in-
crease in the AChE activity in the lymphocytes fromDS subjects. It is pos-
sible that this alteration leads to a decrease of ACh level contributing to
the pro-inﬂammatory status. Although the role of lymphocytic choliner-
gic system is still unclear, alterations in the AChE activity support the
view that this systemmay contribute to the regulation of the immune re-
sponses in DS. These ﬁndings open the doors to the discovery of more
speciﬁc mechanism, as for example the use of AChE inhibitors for the
treatment of immunodeﬁciency in this genetic disorder.
Another important aspect to be discussed is that the increase in the
lymphocytic enzymes observed in this study may be related to alter-
ations in the lymphocyte function and it is not a consequence of immune
cell counting. In fact, our results showed no alterations in the number of
cells (neutrophils, lymphocytes,monocytes, eosinophils andplatelets) or
other hematological parameters such as WBC (white blood cells), RBC
(red blood cells), HCT (hematocrit), MCV (mean corpuscular volume),
CHCM (mean corpuscular hemoglobin concentration), and hemoglobin
when DS individuals were compared with controls.
It is well established in the literature that children with DS have sev-
eral hematological alterations; however, studies evaluating these param-
eters in adults with DS have been poorly documented. Increases in the
VCM [45], neutrophilia [46], leukopenia [47,48], thrombocytopenia [49,
50] and anemia [51] have been described in a number of studies in chil-
dren and newborns with DS. The number of lymphocytes is decreased in
the ﬁrst year of life and the counting of these cells becomes normal over
time [52,53]. Changes in lymphocyte subpopulations such as an increase
in T lymphocytes anda decrease of B lymphocytes have also been report-
ed [53]. These alterations in the lymphocyte number have been attribut-
ed to thymus dysfunction [54–56] and B and T cell apoptosis [57]. In our
study, no differences were observed in the absolute lymphocyte number
in adults. These individuals are likely to possess a compensatory mecha-
nism, such as an increase in IL-7 and IL-15, which have been reported as
inductors of T cell proliferation and survival [53].
5. Conclusion
We demonstrated that NTPDase, AChE and ADA activities and cyto-
kine levels were altered in DS individuals, suggesting that these
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Fig. 4. Cytokine levels in serum fromDS and control subjects. Cytokine quantiﬁcationwas determined by ELISA as described inMaterial andmethods. Data are expressed asmean±SD. IL-
1β, IL-6, TNFα, IL-10 and IFN-γ are expressed in pg/ml. *Represents statistical difference from control group (Student's t test, P b 0.003).
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this condition. The importance of these ﬁndings from clinical and ther-
apeutic points of view should be investigated in further studies andmay
help to devise novel strategies for the treatment of the immunodeﬁcien-
cy characteristic from DS.
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